Pasithea Therapeutics (KTTA) Income from Continuing Operations (2021 - 2024)
Historic Income from Continuing Operations for Pasithea Therapeutics (KTTA) over the last 4 years, with Q4 2024 value amounting to -$3.2 million.
- Pasithea Therapeutics' Income from Continuing Operations rose 3684.17% to -$3.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$13.9 million, marking a year-over-year increase of 1033.78%. This contributed to the annual value of -$13.9 million for FY2024, which is 1033.78% up from last year.
- Latest data reveals that Pasithea Therapeutics reported Income from Continuing Operations of -$3.2 million as of Q4 2024, which was up 3684.17% from -$3.0 million recorded in Q3 2024.
- Pasithea Therapeutics' 5-year Income from Continuing Operations high stood at $630143.0 for Q4 2021, and its period low was -$5.0 million during Q4 2023.
- For the 4-year period, Pasithea Therapeutics' Income from Continuing Operations averaged around -$2.7 million, with its median value being -$3.2 million (2023).
- As far as peak fluctuations go, Pasithea Therapeutics' Income from Continuing Operations tumbled by 74325.15% in 2022, and later soared by 3684.17% in 2024.
- Over the past 4 years, Pasithea Therapeutics' Income from Continuing Operations (Quarter) stood at $630143.0 in 2021, then plummeted by 743.25% to -$4.1 million in 2022, then dropped by 24.12% to -$5.0 million in 2023, then surged by 36.84% to -$3.2 million in 2024.
- Its Income from Continuing Operations stands at -$3.2 million for Q4 2024, versus -$3.0 million for Q3 2024 and -$3.9 million for Q2 2024.